Salivary Binding Antibodies Induced by Human Immunodeficiency Virus Type 1 Recombinant gp120 Vaccine

Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1-uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1(MN) recombinant gp120 (rgp120) vaccine alone or with HIV-1(IIIB) rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.